Theranostic and prognostic biomarkers: genomic applications in urological malignancies

被引：34
作者：
Netto, George J.
Epstein, Jonathan I.
机构：
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA
[3] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
来源：
PATHOLOGY | 2010年 / 42卷 / 04期
关键词：
Theranostics; urological; molecular diagnostics; prognostics; prostate; renal; urothelial; RENAL-CELL CARCINOMA; INVASIVE BLADDER-CANCER; IN-SITU HYBRIDIZATION; P53 NUCLEAR OVEREXPRESSION; PROSTATE-SPECIFIC ANTIGEN; CPG ISLAND HYPERMETHYLATION; DISEASE-SPECIFIC SURVIVAL; TMPRSS2-ERG GENE FUSION; CARBONIC-ANHYDRASE-IX; MICROVESSEL DENSITY;
D O I：
10.3109/00313021003779145
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Compared to other solid tumours such as breast, colon, and lung, the current clinical management of urological malignancies is lagging behind in terms of utilisation of clinically robust molecular tests that can identify patients that are more likely to respond to a given targeted agent, or even those in need of a more aggressive treatment approach based on well-validated molecular prognosticators. Several promising biomarkers for detection, prognosis, and targeted therapeutics are now under evaluation. The following review discusses some of the candidate biomarkers that may soon make their transition into clinically applicable assays in urological oncology patients.</.
引用
收藏
页码：384 / 394
页数：11
相关论文
共 180 条
[31]   Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies [J].
Casella, R ;
Bubendorf, L ;
Sauter, G ;
Moch, H ;
Mihatsch, MJ ;
Gasser, TC .
JOURNAL OF UROLOGY, 1998, 160 (02) :406-410
[32]   Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma [J].
Chatterjee, SJ ;
Datar, R ;
Youssefzadeh, D ;
George, B ;
Goebell, PJ ;
Stein, JP ;
Young, LL ;
Shi, SR ;
Gee, C ;
Groshen, S ;
Skinner, DG ;
Cote, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1007-1013
[33]  
Cheng L, 1999, CLIN CANCER RES, V5, P2820
[34]  
Cheng L, 2000, CLIN CANCER RES, V6, P1896
[35]   Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma [J].
Cheville, JC ;
Lohse, CM ;
Zincke, H ;
Weaver, AL ;
Blute, ML .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) :612-624
[36]   Expression of E-cadherin and α-, β-, γ-catenins in patients with bladder cancer -: Identification of γ-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors [J].
Clairotte, A ;
Lascombe, I ;
Fauconnet, S ;
Mauny, F ;
Félix, S ;
Algros, MP ;
Bittard, H ;
Kantelip, B .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (01) :119-126
[37]   Renal-cell carcinoma [J].
Cohen, HT ;
McGovern, FJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490
[38]   NEUROENDOCRINE CELLS - A NEW PROGNOSTIC PARAMETER IN PROSTATE-CANCER [J].
COHEN, RJ ;
GLEZERSON, G ;
HAFFEJEE, Z .
BRITISH JOURNAL OF UROLOGY, 1991, 68 (03) :258-262
[39]   MOLECULAR-GENETIC ALTERATIONS OF CHROMOSOME-17 AND P53 NUCLEAR OVEREXPRESSION IN HUMAN BLADDER-CANCER [J].
DALBAGNI, G ;
PRESTI, JC ;
REUTER, VE ;
ZHANG, ZF ;
SARKIS, AS ;
FAIR, WR ;
CORDONCARDO, C .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1993, 2 (01) :4-13
[40]  
de Kok JB, 2002, CANCER RES, V62, P2695
12345678910